Lipella Pharmaceuticals Valuation
| LIPO Stock | 3.19 0.06 1.92% |
At this time, the firm appears to be undervalued. Lipella Pharmaceuticals secures a last-minute Real Value of USD6.45 per share. The latest price of the firm is USD3.19. Our model forecasts the value of Lipella Pharmaceuticals from analyzing the firm fundamentals such as Shares Outstanding of 1.21 M, operating margin of (6.98) %, and Return On Equity of -1.72 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lipella Pharmaceuticals' valuation include:
Price Book 2.5936 | Enterprise Value | Enterprise Value Ebitda (4.40) | Price Sales 7.9756 | Enterprise Value Revenue 5.1724 |
Undervalued
Today
Please note that Lipella Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Lipella Pharmaceuticals is based on 3 months time horizon. Increasing Lipella Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lipella Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lipella Stock. However, Lipella Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.19 | Real 6.45 | Target 16.0 | Hype 3.3 | Naive 2.51 |
The intrinsic value of Lipella Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lipella Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lipella Pharmaceuticals Common helps investors to forecast how Lipella stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lipella Pharmaceuticals more accurately as focusing exclusively on Lipella Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lipella Pharmaceuticals' intrinsic value based on its ongoing forecasts of Lipella Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lipella Pharmaceuticals' closest peers.
Lipella Pharmaceuticals Cash |
|
Lipella Valuation Trend
Knowing Lipella Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Lipella Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Lipella Pharmaceuticals Total Value Analysis
Lipella Pharmaceuticals Common is now projected to have valuation of 2.57 M with market capitalization of 3.57 M, debt of 136.59 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Lipella Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.57 M | 3.57 M | 136.59 K |
Lipella Pharmaceuticals Investor Information
About 29.0% of the company outstanding shares are owned by corporate insiders. The book value of Lipella Pharmaceuticals was now reported as 1.79. The company recorded a loss per share of 4.88. Lipella Pharmaceuticals had not issued any dividends in recent years. The entity had 1:8 split on the 8th of November 2024. Based on the key indicators related to Lipella Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Lipella Pharmaceuticals Common is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Lipella Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lipella Pharmaceuticals has an asset utilization ratio of 12.57 percent. This suggests that the Company is making USD0.13 for each dollar of assets. An increasing asset utilization means that Lipella Pharmaceuticals Common is more efficient with each dollar of assets it utilizes for everyday operations.Lipella Pharmaceuticals Ownership Allocation
Lipella Pharmaceuticals Common holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Lipella Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 449.62 K. Net Loss for the year was (4.62 M) with loss before overhead, payroll, taxes, and interest of (2.36 M).About Lipella Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Lipella Pharmaceuticals Common. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Lipella Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Lipella Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Lipella Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lipella Pharmaceuticals. We calculate exposure to Lipella Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lipella Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2.3 M | -2.2 M | |
| Pretax Profit Margin | (11.81) | (12.40) | |
| Operating Profit Margin | (12.14) | (12.75) | |
| Net Loss | (11.81) | (12.40) | |
| Gross Profit Margin | (6.62) | (6.95) |
Lipella Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 6 M |
Lipella Pharmaceuticals Current Valuation Indicators
Lipella Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Lipella Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lipella Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lipella Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lipella Pharmaceuticals' worth.When determining whether Lipella Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipella Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipella Pharmaceuticals Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipella Pharmaceuticals Common Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.88) | Revenue Per Share | Quarterly Revenue Growth 0.279 | Return On Assets | Return On Equity |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.